Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 May 13;22(8):1449–1454. doi: 10.1016/j.bbmt.2016.05.001

Figure 2.

Figure 2

Overall survival (A) and cumulative incidence of relapse (B) stratified by remission duration of ≤6 months or >6 months, demonstrating significantly improved survival and lower incidence of relapse for patients with remission durations greater than 6 months following their initial allo-HSCT (p<0.001).